Skip to content

Efficacy of topical timolol in acne scars are treating with TCACROSS.

Efficacy of topical timolol in atrophic acne scars are treating with TCACROSS.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20191208045657N1
Enrollment
30
Registered
2020-07-21
Start date
2019-02-20
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrophic acne scar. Scar conditions and fibrosis of skin

Interventions

Intervention 1: Intervention group: 20 minutes before treatment for local anesthesia, a cream containing a combination of Lidocaine2.5% and Prilocaine 2.5% is applied to the affected area. The skin su

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Bilateral facial atrophic acne scars Minimum age 18 years

Exclusion criteria

Exclusion criteria: Active acne lesions Prone to make colloids Immunocompromised Active herpes infection Pregnancy or lactation Systemic treatment of isotretinoin or immunosuppressant drugs for the past 6 months. History of sensitivity to any of the materials used in the study major depression Patients with low blood pressure and bradycardia or any history of them History of CHF History of MI History of cardiac arrhythmia Patients with asthma or bronchospasm or or history of them

Design outcomes

Primary

MeasureTime frame
Number of facial atrophic scars. Timepoint: The severity of acne scars is assessed at the beginning of the study, 2 weeks later, and at week 12. Method of measurement: Qualitative Global Scarring Grading System (Goodman and Baron).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohamadhasan Shahverdi

Iran University of Medical Sciences

shahverdy@gmail.com+98 21 2218 5180

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026